# A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

> **NCT04444895** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 73 (actual)

## Conditions studied

- Angioedema

## Interventions

- **DRUG:** Lanadelumab

## Key facts

- **NCT ID:** NCT04444895
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-05
- **Primary completion:** 2023-05-05
- **Final completion:** 2023-05-05
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444895, "A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04444895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*